Denmark
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the development of antibody-based therapies for cancer and other diseases. Founded in 1998, the company focuses on innovative treatments to improve patient outcomes.
Key Products
- EPKINLY & TEPKINLY: For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL).
- Tivdak: For recurrent/metastatic cervical cancer patients with disease progression post-chemotherapy.
- DARZALEX/DARZALEX FASPRO: For multiple myeloma (MM) and light-chain Amyloidosis.
- RYBREVANT: For non-small cell lung cancer (NSCLC).
- TECVAYLI & TALVEY: For relapsed/refractory multiple myeloma (R/R MM).
- Kesimpta: For relapsing multiple sclerosis.
- TEPEZZA: For thyroid eye disease.
Pipeline & Development
Genmab is advancing a robust pipeline of therapies, including:
- Epcoritamab: Targeting DLBCL, FL, B-cell non-Hodgkin lymphoma, and other B-cell malignancies.
- Tisotumab Vedotin: For solid tumors.
- Acasunlimab: For NSCLC and solid tumors.
- Rinatabart Sesutecan: For platinum-resistant ovarian cancer.
- GEN1042, GEN1059, GEN1055, GEN1057: For solid tumors.
- GEN3014: For hematologic malignancies.
- Amivantamab: For head and neck cancer and colorectal cancer.
- Mim8: For hemophilia A.
Strategic Collaborations
Genmab partners with leading pharmaceutical companies, including:
- AbbVie Inc.
- Pfizer Inc.
- BioNTech SE
- Johnson & Johnson
- Novartis International AG
- Bristol Myers Squibb
- Novo Nordisk A/S
With a commitment to cutting-edge research, Genmab continues to expand its portfolio and improve treatment options for patients worldwide.
